VISION
Inspiring transformational change in the
field of oncology diagnostics
MISSION
To develop and deliver accurate, rapid, minimally
invasive oncology diagnostic products utilising our
patented MCM5 antibodies
Arquer Diagnostics is focused on the development and commercialisation of highly accurate minichromosome maintenance (MCM) protein based non-invasive tests for cancer diagnosis and monitoring.
Arquer aim to meet demand expressed by patients, clinicians and payers for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes.
Latest News
@ArquerDx
Today we are celebrating #BiomedicalScience Day here at #ArquerDiagnostics! Over 70% of diagnoses are based on biom… https://t.co/PM8ZkYMOLz
@ArquerDx
RT @BdailyNorthEast: #Sunderland #cancer diagnostics firm @ArquerDx expands into new #European markets https://t.co/g8QqNAmcGM https://t.c…
@ArquerDx
When we talk about #ADXBLADDER, biomarker & MCM5 technology, you might find it going in one ear & out the other. Vi… https://t.co/HPybjUn9xS